VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13
VBL Therapeutics (Nasdaq: VBLT) will host a conference call on August 13, 2020, at 8:30 AM ET to discuss its second-quarter financial results and provide a corporate update. The biotech firm, focused on cancer treatment, is developing ofranergene obadenovec (VB-111), a first-in-class gene therapy for various solid tumors, currently in a phase 3 trial for platinum-resistant ovarian cancer. The therapy has shown positive tolerance and signals in prior studies involving over 300 patients.
- Ofranergene obadenovec (VB-111) is in a phase 3 trial for platinum-resistant ovarian cancer.
- The therapy demonstrated activity signals in prior phase 1 and phase 2 studies.
- VB-111 has been well-tolerated in over 300 cancer patients.
- None.
TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 13, 2020 at 8:30am Eastern Time to report second quarter ended June 30, 2020 financial results and to provide a corporate update.
| Thursday, August 13 @ 8:30amET | ||
| From the US: | 877-407-9208 | |
| International: | 201-493-6784 | |
| Israel: | 1 809 406 247 | |
| Conference ID: | 13707066 | |
| Webcast: | https://edge.media-server.com/mmc/p/y7tts2sv | |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in a VBL-sponsored “all comers” phase 1 trial as well as in three VBL-sponsored tumor-specific phase 2 studies. Ofranergene obadenovec is currently being studied in a VBL-sponsored phase 3 potential registration trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
FAQ
When will VBL Therapeutics report its second-quarter financial results?
What is the primary focus of VBL Therapeutics?
What is ofranergene obadenovec (VB-111) used for?
